Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy

Ophthalmic Research

Volumn 49, Issue 1, 2012, Pages 30-36

  Ushida, Hiroaki ^a   Kachi, Shu ^a   Asami, Tetsu ^a   Ishikawa, Kohei ^a   Kondo, Mineo ^a   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Intravitreal bevacizumab; Proliferative diabetic retinopathy; Visual function; Vitrectomy

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG SCREENING; ELECTRORETINOGRAM; ENDOPHTHALMITIS; EYE FUNDUS; EYE PROTECTION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; PERIMETRY; PREOPERATIVE CARE; PRIORITY JOURNAL; RETINA TEAR; SYSTEMIC DISEASE; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VISUAL FIELD; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VISUAL FIELDS; VITRECTOMY;

EID: 84866898708     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000324135     Document Type: Article

References (17)

1. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450.
2. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW: Vascular endothe-lial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38:36-47.
3. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR: Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-868.
4. Frank RN: Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. Ophthalmic Res 1997; 29: 341-353.
5. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147.
6. Avery RL, Pieramici DJ, Rabena MD, Castel-larin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372.
7. Iturralde D, Spaide RF, Meyerle CB, Klanc-nik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-284.
8. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A: Intravitreal bevacizumab (Avas-tin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26:999-1005.
9. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A: Intrav itrea l bevacizu mab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695.
10. Sawada O, Kawamura H, Kakinoki M, Sawa-da T, Ohji M: Vascular endothelial growth factor in aqueous humor before and after in-travitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007; 125: 1363-1366.
11. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neu-roprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53-67.
12. Iriyama A, Chen YN, Tamaki Y, Yanagi Y: Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007; 91: 1230-1233.
13. Ueno S, Pease ME, Wersinger DM, Masuda T, Vinores SA, Licht T, Zack DJ, Quigley H, Keshet E, Campochiaro PA: Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 2008; 217: 13-22.
14. Chen E, Park CH: Use of intravitreal bevaci-zumab as a preoperative adjunct for traction-al retinal detachment repair in severe prolif-erative diabetic retinopathy. Retina 2006; 26: 699-700.
15. Böcker-Meffert S, Rosenstiel P, Röhl C, Warneke N, Held-Feindt J, Sievers J, Lucius R: Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest Ophthalmol Vis Sci 2002; 43:2021-2026.
16. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G: Injection of intravitreal bevacizumab (Avastin) as a pre-operative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophtha lmol 2008; 246: 837-842.
17. Kroll P, Wiegand W, Schmidt J: Vitreopapil-lary traction in proliferative diabetic vitreo-retinopat hy. Br J Ophthalmol 1999; 83: 261-264.